Search results for "CISPLATIN"

showing 10 items of 267 documents

Synchronous Two Distinct Neuroendocrine Lung Cancer Lesions

2015

Synchroniczne nowotwory płuc są rzadką chorobą, a prezentowany przypadek to pierwszy opublikowany opis jednoczesnego wystąpienia dwóch pierwotnych neuroendokrynnych raków płuca zlokalizowanych w jednym płacie. Przedstawiono przypadek 55-letniej pacjentki z dwoma pierwotnymi, odrębnymi neuroendokrynnymi rakami płata górnego płuca prawego. Pacjentka została przyjęta na oddział chirurgii klatki piersiowej w celu diagnostyki dwóch cieni okrągłych płuca prawego (o średnicy 11 i 19 mm) uwidocznionych na zdjęciu RTG klatki piersiowej wykonanym trzy miesiące wcześniej. Przy przyjęciu pacjentka nie prezentowała żadnych objawów związanych ze zmianami w płucu. Dalsze badania obrazowe wykazały zmiennoś…

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtyLung NeoplasmsLung biopsySmall-cell carcinomasynchronous primary lung cancerNeoplasms Multiple PrimarymedicineHumansCarcinoma Small CellLung cancerdrobnokomórkowy rak płucalarge cell neuroendocrine carcinomasmall cell carcinomaEtoposideCisplatinLungbusiness.industrywielkokomórkowy neuroendokrynny rak płucaNeoplasms Second PrimaryMiddle Agedmedicine.diseaseCarcinoma Neuroendocrinemedicine.anatomical_structureCardiothoracic surgeryFemaleProphylactic cranial irradiationTomography X-Ray Computedbusinesssynchroniczny rak płucamedicine.drugAdvances in Respiratory Medicine
researchProduct

Novel ruthenium methylcyclopentadienyl complex bearing a bipyridine perfluorinated ligand shows strong activity towards colorectal cancer cells

2017

Three new compounds have been synthesized and completely characterized by analytical and spectroscopic techniques. The new bipyridine-perfluorinated ligand L1 and the new organometallic complex [Ru(η 5 -MeCp)(PPh 3 ) 2 Cl] (Ru1) crystalize in the centrosymmetric triclinic space group P1¯. Analysis of the phenotypic effects induced by both organometallic complexes Ru1 and [Ru(η 5 -MeCp)(PPh 3 )(L1)][CF 3 SO 3 ] (Ru2), on human colorectal cancer cells (SW480 and RKO) survival, showed that Ru2 has a potent anti-proliferative activity, 4–6 times higher than cisplatin, and induce apoptosis in these cells. Data obtained in a noncancerous cell line derived from normal colon epithelial cells (NCM46…

PyridinesApoptosisLigands01 natural sciencesBipyridinechemistry.chemical_compoundDrug DiscoverySelectivityta116Molecular StructureCancro colo-retalChemistryapoptosisCycloparaffinsGeneral Medicine3. Good healthRutheniumsyöpäsolutColorectal NeoplasmsSelectivitymedicine.drugStereochemistryCompostos organometálicoschemistry.chemical_elementAntineoplastic Agentscolorectal cancerTriclinic crystal systemorganometalliyhdisteet010402 general chemistryRutheniumStructure-Activity Relationshipohjelmoitunut solukuolemaCell Line TumorOrganometallic CompoundsmedicineHumansCell ProliferationPharmacologyCisplatinScience & TechnologyDose-Response Relationship DrugApoptose010405 organic chemistryLigandRuthenium methylcyclopentadienylOrganic Chemistryta1182selectivitykompleksiyhdisteetColorectal cancer0104 chemical sciencesperäsuolisyöpäApoptosisCell cultureDrug Screening Assays Antitumorruthenium methylcyclopentadienyl
researchProduct

Potential anticancer heterometallic Fe-Au and Fe-Pd agents: Initial mechanistic insights

2013

A series of gold(III) and palladium(II) heterometallic complexes with new iminophosphorane ligands derived from ferrocenylphosphanes [{Cp-P(Ph2)═N-Ph}2Fe] (1), [{Cp-P(Ph2)═N-CH2-2-NC5H4}2Fe] (2), and [{Cp-P(Ph2)═N-CH2-2-NC5H4}Fe(Cp)] (3) have been synthesized and structurally characterized. Ligands 2 and 3 afford stable coordination complexes [AuCl2(3)]ClO4, [{AuCl2}2(2)](ClO4)2, [PdCl2(3)], and [{PdCl2}2(2)]. The complexes have been evaluated for their antiproliferative properties in human ovarian cancer cells sensitive and resistant to cisplatin (A2780S/R), in human breast cancer cells (MCF7) and in a nontumorigenic human embryonic kidney cell line (HEK-293T). The highly cytotoxic trimeta…

STRUCTURAL-CHARACTERIZATIONARENE-RUTHENIUM COMPLEXESStereochemistryANTITUMOR-ACTIVITYchemistry.chemical_elementGOLD COMPOUNDSAntineoplastic AgentsCYTOTOXIC ACTIVITYArticleCoordination ComplexesCell Line TumorDrug DiscoveryOrganometallic CompoundsmedicineHumansCytotoxic T cellFerrous CompoundsBIOLOGICAL-PROPERTIESGroup 2 organometallic chemistryCisplatinHEK 293 cellsIn vitroPLATINUM(II) COMPLEXESHEK293 CellschemistryCELL-DEATHCell cultureCancer cellMolecular MedicineMETAL-COMPLEXESCisplatinOrganogold CompoundsPalladiumX-RAY-STRUCTUREPalladiummedicine.drug
researchProduct

Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly…

2016

Background: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. Materials and Methods: Inclusion criteria of this prospective study were age ≥70 years, Karnofsky performance status 70 to 100, locally advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was 40 mg/mq. Results: A total of 30 patients were recruited. Median follow-up was 32 mo…

Simultaneous integrated boostMalemedicine.medical_specialtyCancer ResearchBrachytherapyUterine Cervical NeoplasmsVMATelderly patients030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineWeekly cisplatinmedicineArc therapyHumansAgedCervical cancerRadical treatmentAged 80 and overbusiness.industryRadiotherapy DosageArticlesmedicine.diseaseVolumetric modulated arc therapyCombined Modality TherapySurgeryOncology030220 oncology & carcinogenesisCarcinoma Squamous CellVMAT; advanced cervical cancer; elderly patients; gynecological malignanciesFemaleadvanced cervical cancer; elderly patients; gynecological malignancies; VMAT; Oncology; Cancer ResearchRadiologyDose Fractionation RadiationLymph NodesRadiotherapy Intensity-ModulatedCisplatinbusinessgynecological malignanciesadvanced cervical cancer
researchProduct

Novel Acylated Triterpene Glycosides from Muraltia heisteria

2002

Four new acylated triterpene glycosides (1-4) have been isolated as two inseparable mixtures of the trans- and cis-3,4,5-trimethoxycinnamoyl derivatives (1,2 and 3,4) from the roots of Muraltia heisteria. The structures of these compounds were elucidated by various 1D and 2D NMR techniques, including (1)H and (13)C, COSY, NOESY, HSQC, TOCSY, and HMBC experiments and FABMS. Compounds 3 and 4 were shown to be cytotoxic in a human colon cancer cell line but did not show any ability to potentiate in vitro cisplatin cytotoxicity.

StereochemistryAcylationSaponinPharmaceutical ScienceStereoisomerismPharmacognosyPlant RootsAnalytical ChemistrySouth AfricaTriterpeneDrug DiscoveryTumor Cells CulturedHumansOrganic chemistryNuclear Magnetic Resonance BiomolecularChromatography High Pressure LiquidPharmacologychemistry.chemical_classificationMolecular StructureChemistryHydrolysisOrganic ChemistryGlycosideStereoisomerismBiological activitySaponinsAntineoplastic Agents PhytogenicTriterpenesTerpenoidPolygalaceaeComplementary and alternative medicineMolecular MedicineCisplatinDrug Screening Assays AntitumorHT29 CellsTwo-dimensional nuclear magnetic resonance spectroscopyJournal of Natural Products
researchProduct

Synthesis and biological evaluation of 4-nitro-substituted 1, 3-diaryltriazenes as a novel class of potent antitumor agents

2011

Abstract We describe the synthesis and biological activity of a new class of 1,3-diaryltriazenes, namely 4-nitro-substituted 1,3-diaryltriazenes. Structure–activity relationship analysis reveals that 1,3-diaryltriazenes can be modified from inactive to highly cytotoxic compounds by the introduction of two nitro groups at the para positions of benzene rings and two additional electron-withdrawing groups (bromo, chloro, trifluoromethyl or fluoro substituents) at their ortho position. In order to increase the solubility of the modified compounds, we introduced various acyl groups to their triazene nitrogen. The results of LC-MS/MS analysis showed that N -acyltriazenes can be considered as prod…

StereochemistryNitro compoundAntineoplastic AgentsApoptosis1 ; 3-diaryltriazenes ; synthesis ; cytotoxicity ; ROS induction ; apoptosisChemical synthesisNitrophenolschemistry.chemical_compoundStructure-Activity RelationshipCell Line TumorDrug DiscoveryCytotoxic T cellHumansProdrugsTriazeneCell ProliferationPharmacologychemistry.chemical_classificationChemistryOrganic ChemistryBiological activityGeneral MedicineDNA NeoplasmProdrugEndoplasmic Reticulum StressIn vitroDrug Resistance NeoplasmNitroCisplatinTriazenesReactive Oxygen Species
researchProduct

Three New Triterpene Saponins from Two Species of Carpolobia

2002

Three new acetylated triterpene saponins 1-3 were isolated from the roots of Carpolobia alba and C. lutea. Their structures were established mainly by 2D NMR techniques as 3-O-beta-D-glucopyranosylpresenegenin-28-O-beta-D-galactopyranosyl-(1-->4)-[beta-D-xylopyranosyl-(1-->3)]-beta-D-xylopyranosyl-(1-->4)-alpha-L-rhamnopyranosyl-(1-->2)-(3,4-di-O-acetyl)-beta-D-fucopyranosyl ester, 3-O-beta-D-glucopyranosylpresenegenin-28-O-beta-D-galactopyranosyl-(1-->4)-[alpha-L-arabinopyranosyl-(1-->3)]-beta-D-xylopyranosyl-(1-->4)-alpha-L-rhamnopyranosyl-(1-->2)-(3,4-di-O-acetyl)-beta-D-fucopyranosyl ester, and 3-O-beta-D-glucopyranosylpresenegenin-28-O-beta-D-xylopyranosyl-(1-->4)-[beta-D-apiofuranosyl…

StereochemistrySaponinNigeriaPharmaceutical SciencePharmacognosyAnalytical ChemistryCarpolobiaTriterpeneDrug DiscoveryTumor Cells CulturedHumansTrisaccharideOleanolic AcidNuclear Magnetic Resonance BiomolecularPharmacologychemistry.chemical_classificationPlants MedicinalMolecular StructurebiologyHydrolysisOrganic ChemistryGlycosideStereoisomerismSaponinsbiology.organism_classificationAntineoplastic Agents PhytogenicTriterpenesTerpenoidPolygalaceaeComplementary and alternative medicinechemistryColonic NeoplasmsMolecular MedicinePolygalaceaeChromatography Thin LayerCisplatinDrug Screening Assays AntitumorJournal of Natural Products
researchProduct

Cytotoxicity and NMR Studies of Platinum Complexes with Cyclooctadiene Ligands

2014

The synthesis of a series of platinum complexes containing cyclooctadiene ligands with the general structure PtMeL(R-cod) (where L = Cl, I, nC3F7, iC3F7, nC8F17, Me, aryl, alkynyl and R = H, Me, Et, iPr, nBu, iBu, nHex, Ph) is presented. All complexes are remarkably stable and were obtained in excellent yields. Their structure in both solution and the solid state were explored by crystal structures and multinuclear (1H, 13C, 19F, 195Pt) NMR spectroscopy. Cytotoxicity experiments with selected complexes in HeLa cells revealed higher toxicity in comparison to that of cisplatin for most of the structures.

Stereochemistrychemistry.chemical_elementCrystal structure010402 general chemistry01 natural sciencesMedicinal chemistryInorganic ChemistryHeLachemistry.chemical_compoundmedicinePhysical and Theoretical ChemistryCytotoxicityta116Cisplatinbiology010405 organic chemistryArylOrganic ChemistryNuclear magnetic resonance spectroscopybiology.organism_classification3. Good health0104 chemical scienceschemistryPlatinumCyclooctadienemedicine.drugOrganometallics
researchProduct

Synthesis, structural characterisation and biological studies of new mononuclear platinum(II) complexes with sterically hindered heterocyclic ligands

2011

Abstract Three novel cisplatin analogues were synthesized, designed according to an approach which violates the “classical” structure–activity relationship, by replacing the diamine ligands with a planar N donor heterocycle giving a sterically hindered complex. Moreover, the sterical hindrance of antitumor drug candidates potentially makes them less susceptible to deactivation by sulphur-containing proteins and helping to overcome resistance mechanisms. The resulting mononuclear complexes of sterically hindered polidentate heterocyclic N ligands [PtCl(bbp)]Cl ( 1 ) [bbp = 2,6-bis(2-benzimidazolyl)pyridine], [PtCl 2 (dptdn)](H 2 O) ( 2 ) [dptdn = sodium 5,6-diphenyl-3-(2′-pyridyl)-1,2,4-tria…

Steric effectsCisplatinStereochemistryCytotoxicitychemistry.chemical_elementBiological activityPolydentate nitrogen ligandInorganic Chemistrychemistry.chemical_compoundchemistryPolynuclear platinum complexeSettore CHIM/03 - Chimica Generale E InorganicaDiaminePyridineMaterials ChemistrymedicinePhysical and Theoretical ChemistryBifunctionalCytotoxicityPlatinummedicine.drugPolydentate nitrogen ligands; Polynuclear platinum complexes; Cytotoxicity
researchProduct

Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin

2021

Nanoparticles (NPs) have emerged as a potential tool to improve cancer treatment. Among the proposed uses in imaging and therapy, their use as a drug delivery scaffold has been extensively highlighted. However, there are still some controversial points which need a deeper understanding before clinical application can occur. Here the use of gold nanoparticles (AuNPs) to detoxify the antitumoral agent cisplatin, linked to a nanoparticle via a pH-sensitive coordination bond for endosomal release, is presented. The NP conjugate design has important effects on pharmacokinetics, conjugate evolution and biodistribution and results in an absence of observed toxicity. Besides, AuNPs present unique o…

Time FactorsCancer TreatmentMetal Nanoparticleslcsh:MedicinePharmacologyMiceNanotechnologyTissue Distributionlcsh:Sciencemedia_commonDrug DistributionDrug CarriersMultidisciplinaryChemistryDNA NeoplasmOrgan SizeHydrogen-Ion ConcentrationEndocytosisOncologyColloidal goldDrug deliveryInactivation MetabolicMedicinemedicine.drugResearch ArticleBiotechnologyDrugBiodistributionDrugs and Devicesmedia_common.quotation_subjectMaterials ScienceAntineoplastic AgentsMaterial by AttributePharmacokineticsCell Line TumormedicineAnimalsHumansPharmacokineticsBiologyNanomaterialsCisplatinUnited States Food and Drug Administrationlcsh:RChemotherapy and Drug TreatmentUnited StatesBionanotechnologylcsh:QGoldNanocarriersCisplatinConjugate
researchProduct